How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment

Diana P Saraiva, M Guadalupe Cabral, António Jacinto, Sofia Braga

ABSTRACT

Triple negative breast cancer (TNBC) is a type of breast cancer (BC) that does not express the oestrogen and the progesterone receptors and the human epidermal growth factor receptor type 2 (HER2). Since there are no positive markers to reliably classify TNBC, these tumours are not yet treated with targeted therapies. Perhaps for this reason they are the most aggressive form of breast carcinomas. However, the clinical observation that these patients do not carry a uniformly dismal prognosis, coupled with data coming from pathology and epidemiology, suggests that this negative definition is not capturing a single clinical entity, but several. We critically evaluate this evidence in this paper, reviewing clinical and epidemiological data and new studies that aim to subclassify TNBC. Moreover, evidence on the role of tumour infiltrating lymphocytes (TILs) on TNBC progression, response to chemotherapy and patient outcome have been published. The heterogeneity, observed even at TILs level, highlights the idea that TNBC is much more than a single disease with a unique treatment. The exploration of the immune environment present at the tumour site could indeed help in answering the question ‘How many diseases is TNBC’ and will help to define prognosis and eventually develop new therapies, by stimulating the immune effector cells or by inhibiting immunological repressor molecules.

In this review, we focus on the prospect of the patient’s diverse immune signatures within the tumour as potential biomarkers and how they could be modulated to fight the disease.

INTRODUCTION

Breast cancer (BC) is the most common malignancy and the second cause of death in women of high income countries. WHO estimates that by 2020 one in every eight women will develop BC. The 5-year survival for BC is 98% for localised disease, 84% for regional disease, but only 23% for distant disease. A quarter of patients with early BC will relapse and half of the women with axillary lymph node involvement will relapse. There are several clinical types of BC, defined by amplification of specific markers. Steroid hormone receptor overexpression (oestrogen and/or progesterone receptors: ER, PgR) define the most abundant type of BC. Roughly 70% of BC is ER-positive and/or PgR-positive, and this type of BC is amenable to hormonal therapy. Human epidermal growth factor receptor type 2 (HER2) amplification, defines a second type, with an incidence of roughly 20% and it is responsive to anti-HER2 directed therapy, namely trastuzumab and, more recently, lapatinib, pertuzumab and TDM1. HER2+ BC can be either ER+ or ER−, but its dominant biological driver and clinical feature is traceable to HER2 gene amplification, a potent oncogene. The disease-free survival at 5 years for these two BC subtypes is over 95%. The ALTTO trial revealed that the addition of lapatinib to trastuzumab in patients with HER2+ BC had no benefit in disease-free survival.

The remaining cases are termed triple negative BC (TNBC), breast carcinomas that neither express ER nor PgR and do not have overexpression of HER2. TNBC can represent between 10% to 20% of all BC cases and it is the subtype with the worse prognosis when compared with OR-positive (and/or PgR-positive) disease and HER2-positive disease. In fact, half a million women die in the world every year with BC, of which 150 000 are estimated to be TNBC cases, representing around 30% of the BC associated deaths. This may be due in part to the fact that it is the only clinical subtype of BC for which there is no approved adjuvant targeted therapy. In fact, in the pre anti-HER2 therapy era, HER2+ BC had an even more dismal survival than TNBC and currently HER2+ BC has a disease-free survival at 5 years comparable to hormone-positive disease. When faced with TNBC, clinicians are limited to the use of surgery, radiotherapy and chemotherapy. However, not all patients with TNBC respond to chemotherapy and this exemplifies what our clinical experience and emerging data suggest—TNBC may be more than a single disease.

Indeed, in the past few years there has been an effort to further divide TNBC cases in order to better understand the distinct
Saraiva DP, et al. ESMO Open 2017;2:e000208. doi:10.1136/esmoopen-2017-000208

Table 1  Clinical, epidemiological and therapeutic heterogeneity of triple negative breast cancer (TNBC)

| Characteristics          | Worse outcome | Better outcome |
|--------------------------|---------------|----------------|
| Age of presentation      | Young         | Old            |
| Stage at presentation    | Advanced      | Early          |
| Growth rate              | Fast          | Slow           |
| First site of metastasis| Liver and brain | Lymph nodes and bone |
| Chemotherapy response    | Resistant     | Sensitive      |
| Body mass index          | High          | Low            |
| Ethnicity                | African       | Caucasian      |

peak risk of relapse is at the third year and in this scenario the clinical outcome worsens. Also, survival after metastasis relapse is reduced when compared with other BC subtypes.8

Considering the age at diagnosis, there is increasing evidence that TNBC may have a bimodal distribution with the first incidence peak in premenopausal patients and a second peak after 70 years of age.20–23 Prognosis of stage-matched premenopausal TNBC is worse than older age TNBC. One can speculate on the underlying biology that explains this difference in outcome. Premenopausal TNBC would be a disease with a few very powerful molecular drivers, more akin to single hit neoplasms; whereas, geriatric TNBC would be a disease of generalised chromosomal instability, a hallmark of ageing tissues and of geriatric cancer.24 In fact, such genomic heterogeneity has been observed in TNBC using deep sequencing.12 25

TNBC has an aggressive behaviour with presentation of de novo metastatic BC, large locally advanced breast lesion or metastastic disease developing shortly after adjuvant chemotherapy.26–28 TNBC frequently metastasises to the viscera, liver, lung or brain.26–32 However, this is not always the case as it may also have an oligometastatic phenotype closer to ER+ BC, with only lymph node and bone disease.33 TNBC is also heterogeneous in terms of time of recurrence (figure 2). Unlike ER+ BC, whose recurrence curve is linear, TNBC has a higher rate of recurrence in the first 5 years and a lower rate of recurrence afterwards; nevertheless, there appears to be two distinct recurrence peaks.23 34 The pattern of late recurrence is generally associated with less aggressive disease, frequently with bone metastases.9 33 The apparent different paths of tumour progression in TNBC might be driven by confounding factors. These differences may be just a proxy for age of

Figure 2  Heterogeneity in the natural history of triple negative breast cancer. Metastasis develop preferentially in the viscera in patients that relapse more rapidly, leading to a bad prognosis. On the other hand, patients with later relapse present TNBC with a tendency to develop bone metastasis, leading to a better prognosis.

Figure 1  An inflammatory triple negative breast cancer of an African woman before (A) and after (B) treatment. Patients that descend from African ethnicity have a higher probability of developing more aggressive forms of breast cancer with lower curability rates. In fact, this patient, although the breast mass decreased (B), did not respond to the treatment and developed very aggressive meningeal carcinomatosis (C) 6 months after diagnosis while still finishing neoadjuvant chemotherapy with an opening pressure in the lumber tap of 40 mm Hg (normal 15–20 mm Hg) and died within 2 weeks of this diagnosis despite intrathecal treatment.

Figure 1  An inflammatory triple negative breast cancer of an African woman before (A) and after (B) treatment. Patients that descend from African ethnicity have a higher probability of developing more aggressive forms of breast cancer with lower curability rates. In fact, this patient, although the breast mass decreased (B), did not respond to the treatment and developed very aggressive meningeal carcinomatosis (C) 6 months after diagnosis while still finishing neoadjuvant chemotherapy with an opening pressure in the lumber tap of 40 mm Hg (normal 15–20 mm Hg) and died within 2 weeks of this diagnosis despite intrathecal treatment.

CLINICAL AND EPIDEMIOLOGICAL HETEROGENEITY IN TNBC

TNBC presents a considerable heterogeneity concerning the age of diagnosis, prognosis and response to treatment, to name a few. The clinical evidence for such heterogeneity is summarised in table 1. Normally and succinctly, TNBC is associated with African women, younger age, higher grade tumours, high mitotic index, more advanced stage at diagnosis, namely inflammatory BC, aggressive biology and poor prognosis, as shown in figure 1.19 The
incidence;\textsuperscript{35} additionally, the group of patients that have late recurrence and good prognosis, may represent the 10% of tumours that are false negatives for ER.\textsuperscript{36}

**African patients**

The association between African women or women with African ancestry and increased susceptibility to more aggressive BC goes back to the 1990s, before BC subtypes were part of our thought process. At this time, it was known that BC in African women was more frequently ER-negative, affected younger women and, when stage and age matched, had worse prognosis.\textsuperscript{37-39} Indeed, African women have more frequently premenopausal aggressive TNBC\textsuperscript{21} 40–42 and their risk of developing TNBC as insulin growth factor receptor type 1 (IGF1) and the has more signalling through growth factor pathways such as insulin growth factor receptor type 1 (IGF1) and the vascular endothelial growth factor-activated genes,\textsuperscript{56} although IGF1 signalling is increased in obese individuals, which was not controlled in this study, and African women have higher body mass index than Caucasians. In fact, the link between obesity and TNBC was shown in the Carolina Breast Study.\textsuperscript{40} Moreover, the stem cell renewal pathway Wnt β-catenin is active in TNBC\textsuperscript{55} and specifically more active in tumours of African patients.\textsuperscript{58} The stem cell marker ALDH1 was studied with tissue microarrays in a cohort of 192 TNBCs from Ugandan patients and was found to be present in 48% of the tumours and correlated with high histological and nuclear grades.\textsuperscript{59}

**Response to chemotherapy**

One of the most striking causes of heterogeneity of TNBC is the different sensitivity to chemotherapy, where patients are either chemoresponsive or chemoresistant.\textsuperscript{60} On one hand, TNBCs are among the most chemoresponsive BCs: data from neoadjuvant studies show that the fraction of tumours experiencing pathological complete response (pCR) is mostly comprised of TNBC.\textsuperscript{50-62} On the other hand, TNBCs are frequently chemoresistant tumours as documented by the short survival of patients with metastatic disease in published series.\textsuperscript{66,67} One could argue that the apparent chemoresponsiveness found in neoadjuvant studies evolves into a chemoresistant phenotype. Nevertheless, this does not seem to be the case since, in large neoadjuvant trials with long follow-up, those women that obtain a pCR consistently maintain survival advantage over the years.\textsuperscript{68} This suggests that chemoresistance is a hard-wired feature of a particular tumour.\textsuperscript{69} Chemoresistance is linked to abundance of stem-like cells that are pluripotent and quiescent and are therefore able to undergo epithelial to mesenchymal transition (EMT) and are resistant to therapy that targets dividing cells. In gene expression studies, these TNBCs enriched in cells that have properties similar to stem cells are classified as claudin low tumours.\textsuperscript{70}

Due to this heterogeneity in response rates to standard chemotherapy, several other therapeutic strategies are being analysed (table 2). These strategies encompass poly (ADP-ribose) polymerase inhibitors (PARPi) and platinum agents (see next section); anti-VEGF drugs,\textsuperscript{71,72} namely bevacizumab; capcetabine\textsuperscript{27}, which is a prodrug that is converted to fluorouracil;\textsuperscript{72} or ixabepilone that stabilises microtubules.\textsuperscript{73} Although these approaches are still being tested in clinical trials, the most promising one is the use of olaparib (a PARPi) in HER2-negative metastatic disease with germline BRCA mutation (gBRCAm).\textsuperscript{75} The other clinical trials are still ongoing or haven’t shown significant differences between patient arms.

Moreover, there is increasing evidence that anticancer immune responses may contribute to the control of cancer after conventional chemotherapy.\textsuperscript{76} Therefore, as we later explore, the fact that TNBC tumours exhibit a high heterogeneous immune microenvironment, may also be associated with the different chemoresistance/chemosensitivity profiles among TNBC.
Due to the different levels of heterogeneity in TNBC here described, it was essential to come up with a subclassification of TNBC in order to develop new targeted therapies, especially in the cases where chemotherapy is not effective.

THE TRIPLE NEGATIVE SUBCLASSIFICATION

In general, BC can be classified into multiple subtypes according to different criteria. TNBC can be further subtyped using histological, developmental and molecular criteria.

Histologically, the majority of TNBC is grade 3 or poorly differentiated (figure 3). The few remaining cases are rare histological types like adenoid-cystic, medullary, apocrine, metaplastic or inflammatory BCs. There have been attempts to establish a relationship between normal mammary gland development and occurrence of BC, that is, to map different types of BCs into different stages of the mammary gland development, as has been done for acute myeloid leukaemia. Some TNBCs would correspond to a more primitive subtype of tumour, closer to the most undifferentiated BC progenitor cell (stem cell). This reasoning is supported by the observation that the putative BC stem cells in vitro models are ER-negative and that, as they subse-

### Table 2  Ongoing clinical trials with PARP inhibitors (PARPi), anti-VEGF, ixabepilone and capecitabine drugs, divided by metastatic, neoadjuvant or adjuvant setting, regimen and efficacy

| Trial ID/number | Phase | Setting | Regimen | Efficacy | Reference |
|-----------------|-------|---------|---------|----------|-----------|
| Olympiad NCT00494234 | III | Metastatic (HER2-negative with gBRCAm) | Olaparib (PARPi) versus chemotherapy | Progression-free survival improved | 76 |
| ABRAZO NCT02034916 | III | Metastatic (with gBRCAm) | Talazoparib (PARPi) in patients previously exposed to platinum or multiple cytotoxic regimens | Talazoparib is well tolerated and has promising antitumour activity | 143 |
| EMBRACA NCT01945775 | III | Metastatic | Talazoparib (PARPi) in patients who have received prior chemotherapy for metastasis | Ongoing, no results published | 144 |
| PARTNER NCT03150576 | II/III | Neoadjuvant (TNBC or gBRCAm) | Adding olaparib (PARPi) to neoadjuvant platinum or multiple prior cytotoxic regimens | Ongoing, no results published | 145 |
| NCT02282345 | II | Neoadjuvant (invasive BC and deleterious BRCAm) | Talazoparib (PARPi) | Ongoing, no results published | 146 |
| NCT00148694 | II | Neoadjuvant (TNBC) | Cisplatin | pCR=22% | 147 |
| NCT02199418 | II | Neoadjuvant | Paclitaxel and cisplatin | pCR=64.7% (in TNBC) | 100 |
| NCT00483223 | II | Metastatic (TNBC) | Cisplatin or carboplatin | ORR=25.6% | 148 |
| NA | NA | Metastatic | Carboplatin and paclitaxel | ORR=56.6% (in TNBC) | 149 |
| BEATRICE NCT00528567 | III | Adjuvant (TNBC) | Bevacizumab (anti-VEGF) | No differences in overall survival; prior patient selection must be performed. | 71 |
| NCT01069796 | II | Metastatic (TNBC) | Bevacizumab, paclitaxel, capecitabine | Ongoing, no results published | 72 |
| TITAN NCT00789581 | III | Adjuvant (TNBC) | Ixempra (ixabepilone) versus Taxol | No differences in disease-free survival and overall survival with Ixempra | 73 |
| NCT00633464 | II | Metastatic (TNBC) | Ixabepilone and ixabepilone + cetuximab (EGFR inhibitor) | Time to response improved in combination, progression-free survival similar | 74 |

BC, breast cancer; gBRCAm, germline BRCA mutation; NA, non applicable; ORR, objective response rate; PARPi, poly (ADP-ribose) polymerase inhibitor; pCR, pathological complete response; TNBC, triple negative breast cancer; EGFR, epidermal growth factor receptor.
being analysed in the new molecular characterisation of TNBC studies and would be concordant with the data on chemoresistance of some TNBCs. The link between breast development and tumorigenesis is conceptually appealing, however more studies need to be performed on this topic.

Although histological and developmental classifications are informative, most of the progress in TNBC subclassification has been performed by molecular studies.

The first molecular observation was based on BRCA1 mutations; however, only for a small number of TNBC cases, since at the most only 20% of patients with TNBC have this mutation. A proportion of the women with TNBC carry BRCA1 germline mutations, but this proportion varies with age of diagnosis and family history (figure 3). The role of BRCA1 null TNBC arising in non-BRCA1 germline mutation carriers is not yet clear. Furthermore, 80% of the BCs arising in BRCA1 germline mutation carriers are TNBC but with good prognosis. Deep sequencing of BC genomes revealed that the BRCA1 null TNBC shows less genomic instability than the non-BRCA1 null TNBC. BRCA1 status may thus be different between two distinct TNBCs. BRCA1-deficient TNBC, germline or somatic, is likely a different biological entity, deficient in DNA repair, and, therefore, responsive to therapy with PARPi and platinum salts. This assumption is being tested in current randomised clinical trials in TNBC. However, clinical trials with PARPi have shown distinct outcomes, as the results are either quite promising or have failed to achieve any response in these patients. Platinum salts are also being used in trials with promising results, as depicted in this meta-analysis. New data on neoadjuvant platinum trials in TNBC have shown a high pCR (table 2). More recently, olaparib and talazoparib, both PARPi, are being used in several clinical trials to treat patients with gBRCAm. The OlympiaAD—a phase III clinical trial that analyses the use of olaparib versus standard chemotherapy in HER2-negative metastatic BC with gBRCAm, found that progression-free survival was improved in the olaparib arm, the time to second progression was longer and there were less adverse events, increasing the health-related quality of life in these patients.

Besides BRCA1 mutations, other TNBC categories have been described. For instance, Lehmann et al molecularly divided TNBC in six different subtypes according to their unique gene expression profiles. These subtypes were classified as basal-like (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR). The first two subclasses had a basal-like phenotype with higher expression of cell cycle and DNA damage response genes and BL2 also had increased growth factor signalling. The IM subtype had elevated immune cell signalling and cytokine signalling. Mesenchymal and MSL subtypes had augmented gene expression for EMT events, cell motility and differentiation. In addition, the MSL class had lower levels of proliferation genes and increased gene expression related with stem cells. Finally, the LAR subclass had increased levels of androgen receptor (AR) and luminal gene expression patterns. Within these subclasses, the response to therapeutic inputs was distinct, as well as the relapse-free survival and distant metastasis-free survival.

More recently, a new classification was described by Burstein et al. In this study, the authors assessed 198 tumour tissues, mainly from Caucasian women, according to their expression profile data. They were able to divide TNBC in four different classes—LAR, mesenchymal (MES), basal-like immunosuppressed (BLIS) and basal-like immune-activated (BLIA). Each subtype had unique gene expression profiles and specific targets. For instance, LAR, which was similar to the subtype described by Lehmann, exhibited AR, ER, prolactin and ErbB4 signalling. MES had increased cell cycle pathways, mismatch repair of DNA, DNA damage networks and higher IGF1. BLIS had low levels of B cells, T cells and natural killer (NK) cells, reduced immune-regulating pathways and cytokine expression; on the other hand, had elevated expression of SOX1. Opposite of BLIS is BLIA with high levels of immune cells and activation of STAT transcription factor mediator pathways. The BLIS subtype had worst prognosis with low disease-free survival, while BLIA had the better prognosis. Specific targets for each class were found: m Tickets for LAR, platelet-derived growth factor (PDGF) receptor A and c-Kit for MES, V-Set domain containing T cell activation inhibitor 1 (VTCN1) for BLIS and STAT signal transduction molecules and cytokines for BLIA.

Interestingly, Lehmann recently published another work where he acknowledges the existence of only four subtypes, denominated TNBCtype-4. These subtypes...
were BL1, BL2, M and LAR. In addition to the gene expression profiles that were executed in the first article, histopathological quantification and laser-capture microdissection (LCM) were used. As so, the lymphocytic infiltration was found to be present in all six subtypes, in different percentages, leading to the conclusion that IM is not really an independent subtype but that its components are present in the other classes. Moreover, the authors found that the characteristics of the MSL subtype were mainly derived by the stromal component surrounding the tumour. Again, each of the subtypes had different responses to the same treatment, with 41% of BL1 patients and only 18% of BL2 patients achieving pCR.

Even though the subtypes described by Burstein or by Lehmann are not exactly superimposable, there seems to be a tendency—one class with high expression of AR, another with mesenchymal features and two basal-like. In addition, lymphocytic infiltration appears to be present in distinct proportions across the subtypes, or at least prevalent in two subclasses (BLIS and BLIA). The important message to retrieve from these attempts to classify TNBC is that indeed tumours differ between patients as well as their response to the same treatment and this could be the basis of the heterogeneity found in the clinic that was described in the previous section. It is possible to hypothesise that young women with TNBC can have a subtype that is more aggressive or that doesn’t have a good response to a systemic untargeted treatment, such as BLIS for instance, when compared with menopausal women with TNBC. Moreover, a tumour with mesenchymal phenotype and with stem cell characteristics can be more chemoresistant than a basal-like subtype. This subtype could be more prevalent in African women, since they have a more aggressive phenotype that is more intolerant to treatment.

Another point in common between all classifications is the presence of immune cells within the tumour, either as a subgroup on its own—IM in Lehmann’s first classification or BLIS and BLIA in Burstein’s study, or widespread through all groups as depicted in the second classification published by Lehmann. Moreover, BLIS and BLIA subtypes were the ones with the worst and best prognoses, respectively. Thus, it seems clear that the immune system plays a critical role in the progression of TNBC.

THE ROLE OF IMMUNE CELLS IN TNBC PROGRESSION

Indeed, a few studies have described the relationship between tumour infiltrating lymphocytes (TILs) and cancer progression and patient survival, namely in melanoma and ovarian, breast, bladder, cervical, colon, prostate, rectum and lung cancers.104–107 TILs enclose cytoxic CD8+ T cells, CD4+ T helper cells (Th), CD4+/FOXP3+ regulatory T cells (Treg), B cells and NK cells. It was observed that in BC and in the adjacent stroma, the number of TILs is higher when compared with normal breast tissue.108 109 Overall, the presence of TILs in BC seem to lead to a better prognosis and an increased survival rate, since chemotherapeutic drugs are more efficient against tumours implanted in immunocompetent, with respect to immunodeficient hosts.110 111 Severe lymphopenia negatively affects the chemotherapeutic response of multiple distinct solid cancers112 and depletion of CD8+ T lymphocytes in animal models also reduced the efficacy of chemotherapy.110 111 Hence, several reports have been advocating that TILs could serve as a robust marker for predicting pCR rate in respect to NACT.113

In a meta-analysis of studies published with predictive significance of TILs in pCR in cases of BC with NACT,114 the authors observed that an increase in TILs (especially CD8+ and FOXP3+ cells) in biopsies from patients with no previous treatment led to better pCR after NACT. Another meta-analysis observed that an increase in TILs led to a reduction of 30% in the risk of recurrence, a decrease in 22% in the risk of distant recurrence and 34% less risk of death.115

Within patients with BC, the presence of TILs has been associated with increased pCR rates and a decreased risk of mortality in HER2+ and TNBC, but not in ER+ disease.114 116–118 We will now focus on the role of TILs specifically in TNBC.

A study observed that in TNBC samples, the presence of CD8+ cells within the tumour was associated with a reduction of 28% in mortality and the presence of these cells in the stroma led to a decrease of 21%.116 The presence of TILs correlates with pCR, and the quantity of TILs in the tumour microenvironment is also important, as it was found that the higher the number of CD8+ T cells present at the tumour site, the better the prognosis of patients with TNBC.119–121 In the past few years, a number of clinical trials in BC, namely in TNBC, started to implement the quantification of TILs and the possible association with survival. For instance, in ECOG 2197 and ECOG 1199 trials, it was observed that for each 10% increment in TILs (within the stroma), there was a 19% reduction in the risk of death.91 Loi et al observed that each 10% increase in TILs was associated with 27% reduction in the risk of death (BIG 02–98 clinical trial)117 and 13% reduction in the relative risk of distant recurrence (FinHER trial).122 If the patients were treated with chemotherapy, this reduction was of 18%.122 Thus, it is possible that the clinical efficacy of therapeutic regimens commonly employed to treat TNBC, namely chemotherapy, is largely determined by T lymphocyte-depending immune response. Indeed, in a prospective study, it was found that an increase in TILs in BC supports a better response to anthracycline/taxane-based NACT.123

However, not all studies corroborate this association between presence of TILs and patient outcome. In fact, and just as an example, Liu et al, determined that there was no association between CD8+ TILs infiltration and improved survival in TNBC that showed no expression of basal markers.120

Moreover, CD8+ T cells are present in immune infiltrates within the tumour, and other T cells, such as
CD4+ Th and FOXP3 are also present in the tumour microenvironment. CD4+ Th may be correlated with good prognosis (higher Th1) and with poor prognosis (higher Th2) in BC, but not specifically in TNBC. Treg effect on prognosis is controversial, with different studies in TNBC affirming distinct consequences from the presence of Tregs in tumours. For instance, Mahmoud et al described that Treg is not an independent prognostic factor, while Lee et al claimed that improved survival in patients with TNBC was associated with highly infiltrating Treg. It was also described that the presence of FOXP3+ in patients post-NACT was found to be a predictive marker for a low pCR rate. Interestingly, it was described that a ratio of CD8+/FOXP3+ ≥3 in primary BC led to an improved overall survival, whereas if this ratio is <3 in metastatic BC (at first relapse), it also led to improved overall survival. In metastatic TNBC, the levels of CD3+, CD4+, CD8+ and FOXP3+ TILs were inferior than the matched primary tumour, and metastatic TNBCs had fewer TILs compared with metastatic HER2+, ER+ or PgR+ tumours.

Besides CD4+, CD8+ and FOXP3+ TILs, other cells from the immune system can have a pivotal role in TNBC progression, as tumour associated macrophages (TAMs), dendritic cells (DCs), tumour associated neutrophils (TANs), myeloid derived suppressor cells (MDSCs) and NK cells. Nevertheless, few studies have been developed that focus on these cells from the immune system and their possible association with patient outcome.

The information input that is used nowadays in the clinic for patients with TNBC is not sufficient to distinguish between patients who have a high chance to have a pCR when treated with conventional NACT from patients who cannot achieve a pCR and could benefit more from alternative immunotherapies. The information provided by the clinical measure of TILs pretreatment could be an answer to help in decision making regarding the treatment of different patients with TNBC. Stratification of patients based on the presence of TILs, and more specifically the subtype and the phenotype of TILs, will be paramount in the future to provide quality treatment to non-responders to conventional systemic therapy. Indeed, immunotherapy is not yet a reality for patients with TNBC, since the clinical trials implemented so far had a low response rate, probably due to poor characterisation of the immune environment and subsequent suboptimal patient stratification.

**POTENTIAL NEW TARGETED THERAPIES FOR TNBC CONSIDERING ITS IMMUNE MICROENVIRONMENT**

The success of NACT may be interrupted by distinct strategies employed by tumour cells to induce anergy/exhaustion of effector CD8+ T cells and Th1 cells, namely by defective antigen presentation, by engaging the T cell receptor in the absence of co-stimulation, by shifting the balance from Th1 to Th2 (immune deviation), by expressing inhibitory molecules like PD-L1 which bind the inhibitory receptor PD-1 in effecter T lymphocytes, inducing negative regulatory pathways that limit the activity of these cells. Other inhibitory immune checkpoints, such as CTLA-4, Tim-3 or LAG-3 and the secretion of extrinsic immunosuppressing molecules such as interleukin (IL) 10, TGF-β, indoleamine 2,3-dioxygenase (IDO) or arginase could also directly or indirectly (by recruiting MDSCs and Tregs) negatively impact effecter T cells’ actions. CTLA-4 is also expressed at the surface of T cells and can suppress their function by binding to B7 ligands. Tumour cells can express these ligands on their surface to escape the immune system. Tim-3 is a cell surface receptor present in CD4+ and CD8+ T cells with an inhibitory function. Tests performed in mouse models of BC found a high number of CD8+ T cells with Tim-3 expression infiltrating the tumour and the blockage of Tim3 led to an increase in antitumour immunity.

IDO is an immunosuppressive enzyme present in DCs, macrophages and tumour cells. By using an IDO inhibitor, it would be possible to increase the level of maturation of these cells that are able to present tumour-associated antigens to effecter cells. Another interesting approach to boost the antitumour response would be by the use of OX40 agonists, since OX40 is a co-stimulatory receptor present in T cells. Using an IDO inhibitor, it would be possible to increase the level of maturation of these cells that are able to present tumour-associated antigens to effecter cells. Another interesting approach to boost the antitumour response would be by the use of OX40 agonists, since OX40 is a co-stimulatory receptor present in T cells. CTLA-4 is also expressed at the surface of T cells and can suppress their function by binding to B7 ligands. Tumour cells can express these ligands on their surface to escape the immune system.

Blocking these immunosuppressing mechanisms to augment T lymphocyte function seems a promising approach to treat cancer. Indeed, these proteins are beginning to be used in anticancer therapeutics, as FDA approved one antibody against CTLA-4 (ipilimumab), two against PD-1 (pembrolizumab and nivolumab) for the treatment of melanoma and also two against PD-L1—atezolizumab and avelumab, for bladder cancer and squamous non-small cell lung cancer treatment, respectively.

As TNBC appears to have high infiltration of cells from the immune system, it would be interesting to analyse the level of these immune checkpoints on TNBC samples. In fact, the PD-L1 inhibitor pembrolizumab is being tested on patients with TNBC in a phase II clinical trial with some promising results. Pembrolizumab is also being analysed as an addition to standard NACT in two different trials—KEYNOTE 173 and I-SPY 2. In the first clinical trial, TNBC pCR rates are 90% (NACT+pembrolizumab) and 100% with carboplatin addition. In the I-SPY 2 trial, pCR rates were 2%. In a metastatic setting (KEYNOTE 86), it was possible to observe that patients that had increased response to pembrolizumab had lower LDH and no liver nor visceral metastasis. Thus, it seems that immunotherapy in a metastatic setting has a higher response in less aggressive cases.

A growing body of evidence shows that the type of immune response influences the efficiency of several chemotherapeutic drugs and therefore selective immunotherapeutic...
interventions alone or in synergism with more conventional anticancer agents are now more appealing.

The blockade antibodies against T cell checkpoint molecules including CTLA-4 and the PD-1/PD-L1 axis in monotherapy or combination therapies have begun to revolutionise the current standard cancer treatment in various cancer types, such as melanoma, lung cancer, bladder cancer and Hodgkin’s lymphoma. This treatment is still not used in TNBC, because the genetic instability of tumour cells, which is frequent in this type of disease, make it a bad candidate for the success of targeted immunotherapies. However, the implementation of patient stratification by evaluating TILs and their phenotype in the clinic may improve the use of immunotherapies in this subtype of BC. Indeed, with the evaluation of the tumour-immune microenvironment it would be possible to distinguish patients that benefit from standard chemotherapy alone from those who would benefit more from these new monoclonal antibodies alone or in combination with chemotherapeutic agents.

Besides these immune checkpoint inhibitors, other approaches could be interesting for the development of new therapies. For instance, the BLIS subtype described by Burstein has an immunosuppressed environment that is translated to the gene expression profile of these tumours. There are some genes important for the regulation and activation of the immune system effectors that are downregulated in BLIS samples compared with controls. Since this subtype is the one with the worst prognosis it is of foremost importance to discover new ways to treat these patients. The external upregulation of these genes may be one of the methods to overcome the immunosuppression in this subtype. Interestingly, some of these genes are upregulated in BLIA, which demonstrates their importance in the activation of the immune environment. Among these genes are CXCL9, CXCL13, GZMB, GZMA, CD2, CD69, PTPRC and TLR8.

CONCLUSIONS
TNBC is still a problem in the clinic, due to the lack of targeted therapies. Additionally, patients with TNBC have a high level of divergence between them, concerning age of diagnosis, the prognosis and the response to treatment. Thus, we are convinced from our clinical observations, laboratory data and from the literature that TNBC is not a single disease and that the subclassification of this clinical entity with clinical phenotype correlates is an unmet clinical need in BC.

In order to understand this heterogeneity and to develop new therapies, researchers have tried to uncover the basis of this diversity, using histological and molecular tools. Although it seems that no consensus has yet been made, some advances point to the same direction and patient segregation can be achieved: TNBC arising in patients with the BRCA1 germline mutation, TNBC associated with an immune phenotype with lymphocytic infiltration or TNBC arising in African-descent patients that is more chemo-resistant.

So, to improve patient welfare, it is likely that several therapeutic strategies will be implemented according to the subtype of TNBC. These therapies can go from PARPi or platinum agents, for BRCA1 mutation carriers, to immune checkpoint inhibitors, that can modulate the tumour immune microenvironment to stimulate immune responses and control tumour progression.

Nevertheless, the findings in this area are still preliminary and more studies need to be performed to ascertain the true effect of these treatments in TNBC treatment.

Contributors DPS, MGC and SB reviewed the literature, wrote the manuscript and AJ revised the text.

Competing interests None declared.

Patient consent Obtained.

Ethics approval Hospital Prof Doutor Fernando da Fonseca.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. World Health Organization. Women and health: today’s evidence tomorrow’s agenda. 2009.
2. Howlader N, Kroonen M, Miller D, et al. SEER Cancer Statistics Review, 1975-2012; National Cancer Institute, 2015.
3. Marques AR, Teixeira E, Diamond J, et al. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat 2009;114:223–32.
4. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4.
5. Sliamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
6. Engebaeten O, Vollan HK, Borresen-Dale AL. Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol 2013;183:1064–74.
7. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016;34:1034–42.
8. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016;293:247–69.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429–34.
10. Oritolo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7(1-2):4–13.
11. Spitala A, Mazolla P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009;20:628–35.
12. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346–52.
13. Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 2008;19:669–74.

14. Ivanov O, Chen F, Wiley EL, et al. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2008;111:411–7.

15. Wysocki PJ, Korski K, Lamperska K, et al. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 2008;14:1079–10.

16. Lehmann BD, Jovanovic B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 2016;11:e0157368.

17. Lehmann BD, Jovanovic B, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750–67.

18. Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015;21:1688–98.

19. Honorio M, Guerra Perea N. Decreased survival in African patients with triple negative breast cancer. J Palliat Care Med 2016;06:2.

20. Anderson WF, Chatterjee N, Ernstberger WB, et al. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002;76:27–36.

21. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2011;121:2750–67.

22. Stephens PJ, McBride DJ, Lin ML, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135–47.

23. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005–10.

24. Collett K, Steffenson JM, Edie J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected cancers. Cancer Epidemiol Biomarkers Prev 2005;14:1108–12.

25. Seewaldt VL, Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med 2007;356:e12.

26. Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 2008;17:3319–24.

27. Gadadaram J, Kozlov SA, Abraham J, et al. Predominance of brain and lung metastases in triple-negative breast cancer patients. Cancer Res 2009;69(24 Supplement):6159.

28. Pinilla SM, Horonado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Cancer Res 2009;69(24 Supplement):6159.

29. Rodriguez-Pinilla SM, Sarrió D, Honrado E, et al. Predominance of brain and lung metastases in triple-negative breast cancer patients. Cancer Res 2009;69(24 Supplement):4044.

30. Tse GM, Tan PH, Lau KM, et al. Breast cancer in the elderly: a histological assessment. Histopathology 2009;55:441–51.

31. Gong Y, Yan K, Lin F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007;8:203–11.

32.Crowe JP, Gentz H, Hubay CA, et al. The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients. Surgery 1986;100:599–605.

33. Natarajan N, Nemoto T, Mettlin C, et al. Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer 1985;56:1704–9.

34. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994;16:69–77.

35. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer Study. JAMA 2006;295:2492–500.

36. Huo D, Ikapat F, Krhamslov A, et al. Population differences in breast cancer; survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009;27:4515–21.

37. Zalzal S, Lund M, May K, et al. The triple threat of recurrence after breast conserving therapy: race, receptor status and age. Cancer Res 2009;69(24 Supplement):6045.

38. Stead LA, Lash TL, Solibier J, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Research 2009;11:111.

39. Kim K, Lee E, Lee J, et al. Clinicopathologic Signature of TNBC: A Good Prognosis. Cancer Res 2009;69(24 Supplement):4065.

40. Kwong A, Wong K, Wong C, et al. The Epidemiology, Clinico-Pathologic and Prognostic Characteristics of Triple-Negative Breast Cancer Compared with Non-Triple-Negative Breast Cancer. Cancer Res 2009;69(24 Supplement):3071.

41. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008;15:303–8.

42. Frascio G, Cornella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009;20:1185–92.

43. Linn SC, Van’t Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 2009;45 Suppl 1:1–26.

44. Cleator S, Heller W, Coombers RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235–44.

45. Boyd NF, Li Q, Mclnichouk O, et al. Evidence that breast tissue stiffness is associated with risk of breast cancer. PLoS One 2014;9:e100937.

46. McGormack VA, dos Santos Silva I, Silva dosS I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159–69.

47. Barlow WE, White E, Ballard-Barbasa R, et al. Prognostic breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204–14.

48. Albain KS, Unger JM, Crowley JJ, et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009;101:984–92.

49. Chlebowsk RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97:439–48.

50. Lindner R, Sullivan C, Offor O, et al. Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PLoS One 2013;8:e71915.

51. King TD, Suto MJ, Lander ES. The catenin/catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012;113:13–18.

52. Wend P, Runke S, Wend K, et al. WNT10B/catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med 2013;5:264–79.

53. Nakwoga H, Arnes JB, Wabinga H, et al. Refinement of triple-negative breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2009;101:111.

54. Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor properties of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). ASCO Annual Meeting Proceedings. LBA515

55. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1725–31.
65. Wang S, Yang H, Tong F, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. *Gan To Kagaku Ryoho* 2009;36:255–8.

66. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. *Clin Breast Cancer* 2009;9:29–33.

67. Lin NU, Claus E, Sohi J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. *Cancer* 2008;113:2638–45.

68. Bear HD, Andorfer S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 2006;24:2019–27.

69. Rüsemann Y, Meier JB, Schubert F, et al. Systemic spread is an early step in breast cancer. *Cancer Cell* 2008;13:58–68.

70. Weigelt B, Geyer FC, Natrajran R, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. *J Pathol* 2010;220:45–57.

71. Cameron D, Brown J, Dent R, et al. Adjuvant bevacicizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol* 2012;13:939–42.

72. ClinicalTrials.gov. Bevacizumab + paclitaxel + + capecitabine in triple negative metastatic breast cancer. [https://clinicaltrials.gov/ct2/show/NCT01069796](https://clinicaltrials.gov/ct2/show/NCT01069796).

73. Yardley DA, Bosserman LD, Keaton MR, et al. TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixabo) or capecitabine (Pac) in the adjuvant setting, triple-negative breast cancer (TNBC). *J Clin Oncol* 2015;33.

74. ClinicalTrials.gov. Randomized phase II study of ixabepilone alone and ixabepilone plus cetuximab as first-line treatment for female subjects with triple negative locally advanced non-resectable and/or metastatic breast cancer. [https://clinicaltrials.gov/ct2/show/NCT00633464](https://clinicaltrials.gov/ct2/show/NCT00633464).

75. Robson ME, Im S-A, Senkus E, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). *Journal of Clinical Oncology* 2017;35:LBA4.

76. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The antitumor immune response: indispensable for therapeutic success? *J Clin Invest* 2008;118:1991–2001.

77. Maehle BO, Thoresen S, Skjaerven R, et al. Mean nuclear area and histological grade of axillary-node tumour in breast cancer, related to progression. *Br J Cancer* 1982;46:95–100.

78. O’Reilly SM, Campolengo RS, Barnes DM, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. *Br J Cancer* 1990;61:587–4.

79. Hance KW, Anderson WF, Devesa SS, et al. Triple negative tumours: a critical review. *Receptors* 2005;97:966–75.

80. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Post-neoadjuvant chemotherapy for patients with locally advanced breast cancer and BRCA mutations. *Oncology* 2016;88:457–64.

81. Worse prognosis of metaplastic breast carcinomas, and lymphomas. *N Engl J Med* 1997;337:115–23.

82. Venkitaraman AR. Targeting the molecular defect in BRCA-deficient tumours for cancer therapy. *Cancer Cell* 2009;16:89–90.

83. Feng PC, Boss DS, Yap TA, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med* 2009;361:123–34.

84. O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med* 2011;364:205–14.

85. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol* 2011;12:852–61.

86. O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. *J Clin Oncol* 2014;32:3840–7.

87. Liu M, Mo QG, Wei CY, et al. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. *Oncol Lett* 2013;5:983–91.

88. Zhou L, Xu S, Yin W, et al. Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. *Oncotarget* 2017.

89. Kiwina Y, Miyahara Y, Wang HY, et al. CD8+ Fopx3+ regulatory T cells mediate immunosuppression in prostate cancer. *Cancer Res* 2007;67:8947–58.

90. Liakou CI, Narayanan S, Ng Tang D, et al. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. *Cancer Immun* 2007;7:10.

91. Sainioma PP, Powell DJ, Dij PJ, et al. Tumor infiltrating lymphocytes in ovarian cancer. *Cancer Biol Ther* 2015;16:897–20.

92. Teng F, Mu D, Meng X, et al. Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. *Am J Cancer Res* 2015;5:2064–74.

93. Tsuyuguchi I, Shiratsuchi H, Fukuoka M, T-lymphocyte subsets in primary lung cancer. *Jpn J Clin Oncol* 1987;7:13–17.

94. Underwood JC. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. *Br J Cancer* 1974;30:538–48.

95. Woo JR, Liss MA, Muldung MT, et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. *J Transl Med* 2014;12:30.

96. Tuuionl E, Velaq D, Beccourt P, et al. Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. *J Immunol* 2009;182:7155–62.

97. Willard-Gallo K, Buisseret L, Garaud S, et al. Abstract PD1-3: The significance of tumor infiltrating lymphocyte density, subset composition and chemotaxis in breast cancer. *Cancer Res* 2011;71:575(Supplement);PD1-3.

98. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. *Immunol Rev* 2007:220:47–59.

99. Casares N, Pequignot MO, Tesniere A, et al. CD45-dependent immunogenicity of doxorubicin-induced tumor cell death. *J Exp Med* 2005;202:1691–701.

100. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. *Cancer Res* 2006;69:583–91.

101. Hornychova H, Melichar B, Tomsova M, et al. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. *Cancer Invest* 2008;26:1024–31.

102. Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) in predicting neoadjuvant response to doxorubicin chemotherapy in breast cancer: a systematic review and meta-analysis. *PLoS One* 2014;9:e115103.
